Skip to main content
. Author manuscript; available in PMC: 2017 Aug 23.
Published in final edited form as: Sci Transl Med. 2017 Jun 28;9(396):eaal3653. doi: 10.1126/scitranslmed.aal3653

Figure 6. Therapeutic post-exposure administration of GS-5734 mitigates disease.

Figure 6

(A) Percent starting weight of 27–28 week old female Ces1c−/− infected with 103 pfu SARS-CoV MA15 treated twice daily with vehicle or 25mg/kg GS-5734 beginning on either -1dpi (vehicle n = 5, GS-5734 n = 10) or +1dpi (vehicle n = 4, GS-5734 n = 11). GS-5734-treated animal weights were statistically different (p<0.05) from vehicle-treated 3 and 4 dpi for prophylactic and 4dpi for therapeutic groups by two-way ANOVA with Tukey’s multiple comparison test. (B) Percent starting weights of mice in panel A at 4 dpi. (C) SARS-CoV lung titer in mice infected and treated as described in panel A. Asterisks indicate statistical significance (p<0.05) by Mann-Whitney test for panels B and C. (D) Whole-body plethysmography (WBP) was used to measure pulmonary function in mice infected and treated as described in panel A. Penh is a surrogate measure of bronchoconstriction or airway obstruction. Asterisks indicate statistical significance by two-way ANOVA with Sidek’s multiple comparison test.